摘要
Recent findings by Yamashita et al report a Kawasaki disease(KD)case with normal biomarker levels,challenging traditional diagnostic paradigms.This editorial explores the implications of such atypical KD presentations,emphasizing the need for novel biomarkers and revised diagnostic guidelines.The case underscores the limitations of current biomarkers,the importance of clinical judgment,and the necessity for comprehensive research to identify new diagnostic tools.Emerging technologies in proteomics and genomics offer potential avenues for discovering reliable biomarkers.Revisiting clinical guidelines to incorporate flexibility for atypical presentations is crucial.Ensuring timely and accurate KD diagnosis,even without elevated traditional biomarkers,prevents severe complications.Future advancements should focus on novel biomarkers to improve patient outcomes.
基金
Supported by The Hubei Pediatric Alliance Medical Research Project,No.HPAMRP202117.
